Clinical Trials Logo

Helicobacter Pylori Infection clinical trials

View clinical trials related to Helicobacter Pylori Infection.

Filter by:

NCT ID: NCT06399562 Completed - Clinical trials for Helicobacter Pylori Infection

Related Factors of Hp Infection in Physical Examination and Community Population in Hunan Province

Start date: April 20, 2024
Phase:
Study type: Observational

This study intends to investigate the prevalence and risk factors of Helicobacter pylori (H. pylori) infection in the population of physical examination centers and communities. The physical examination population from the health management center of the Third Xiangya Hospital and the family-based community residents in Changsha were randomly selected. The H. pylori infection was detected by carbon-13 urea breath test (13C-UBT), and the related factors of H. pylori infection were investigated by questionnaire survey. The study provides supporting evidences to implement family-base H. pylori management to curb its intrafamilial spread. The results have important clinical implications in refinement of eradication strategies and impact on public health policy formulation for related disease prevention.

NCT ID: NCT06397066 Recruiting - Clinical trials for Helicobacter Pylori Infection

White Light Endoscopy and Magnifying Endoscopy in Assessing the Status of Hp Infection

Start date: May 1, 2024
Phase:
Study type: Observational

By comparing the characteristics of Helicobacter pylori (Hp) infection under magnifying endoscopy and white light endoscopy, and making judgments of Hp infection status, the advantages and disadvantages of the two endoscopic examination methods are summarized to improve the accuracy of subsequent endoscopic Hp infection status judgments.

NCT ID: NCT06396780 Active, not recruiting - Clinical trials for Helicobacter Pylori Infection

Treatment Adherence And Influencing Factors in Children With Helicobacter Pylori Infection During Eradication Therapy

Start date: March 30, 2024
Phase:
Study type: Observational

The aim of this study is to describe the current status of treatment adherence in children with Helicobacter pylori infection, understand the medication literacy, medication beliefs of the children, knowledge of H. pylori among caregivers, medication beliefs, medication support, and explore the influencing factors of medication adherence.

NCT ID: NCT06391177 Not yet recruiting - Clinical trials for Helicobacter Pylori Infection

A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily

Start date: May 2024
Phase: Phase 1
Study type: Interventional

The primary objective is to determine the pharmacokinetics (PK) of vonoprazan in breast milk of healthy lactating women who have received vonoprazan administered once daily for 4 consecutive days.

NCT ID: NCT06382493 Recruiting - Clinical trials for Helicobacter Pylori Infection

Tegoprazan-containing Sequential for H. Pylori

Start date: February 1, 2021
Phase: N/A
Study type: Interventional

As H. pylori eradication, the investigators prepared a randomized controlled clinical trial whether tegoprazan-containing 10-day sequential treatment was effective compared to conventional PPI-containing 10-day sequential eradication therapy

NCT ID: NCT06351891 Not yet recruiting - Clinical trials for Helicobacter Pylori Infection

Efficacy and Safety of Bismuth Quadruple Therapy Containing Cefuroxime and Tetracycline as First-line Therapy for Eradicating Helicobacter Pylori in Patients Allergic to Penicillin

Start date: April 2024
Phase: Phase 4
Study type: Interventional

The researchers collected untreated H. pylori positive patients from outpatient clinics. Subjects were randomly assigned to receive either 14 days of bismuth quadruple therapy with cefuroxime and tetracycline or 14 days of bismuth quadruple therapy with cefuroxime and levofloxacin for Helicobacter pylori eradication. After 6 weeks of treatment, subjects underwent another 13C urea breath test. Eradication rates, adverse reaction rates and patient compliance were calculated.

NCT ID: NCT06340724 Not yet recruiting - Clinical trials for Helicobacter Pylori Infection

Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H.Pylori Eradication

Start date: March 2024
Phase: Early Phase 1
Study type: Interventional

Vonoprazan and high-dose amoxicillin dual therapy was used as a control group to evaluate the clinical effiency and safety of Banxiaxiexin decoction combined with vonoprazan and high-dose amoxicillin dual therapy in the treatment of helicobacter pylori infection complicated with functional dyspepsia,through a randomized controlled trail.

NCT ID: NCT06340334 Not yet recruiting - Clinical trials for Helicobacter Pylori Infection

Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study

Start date: March 2024
Phase: N/A
Study type: Interventional

To compare the efficacy and safety of Tegoprazan-amoxicillin dual therapy and bismuth quadruple therapy based on furazolidone in the treatment of Helicobacter pylori eradication, the eradication rate, patient compliance, and adverse drug reactions of H. pylori infection were compared in a multi-center clinical joint study in Jiangsu Province.

NCT ID: NCT06337604 Completed - Clinical trials for Helicobacter Pylori Infection

The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets

Start date: October 10, 2017
Phase: Phase 1
Study type: Interventional

A phase 1, single-center, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and tolerability, pharmacokinetics, and preliminary efficacy of multiple administrations of TNP-2092 Capsules in combination with Rabeprazole Sodium Enteric-coated Tablets in asymptomatic healthy subjects with Helicobacter pylori infection

NCT ID: NCT06332599 Recruiting - Clinical trials for Helicobacter Pylori Infection

Minocycline for Helicobacter Pylori Rescue Treatment

Start date: October 1, 2021
Phase:
Study type: Observational

Current guidelines have recommended classical bismuth-containing quadruple therapy including proton-pump inhibitor, bismuth, tetracycline, metronidazole as the empirical rescue therapy. However, tetracycline is clinically unavailable in China and the high frequency of adverse events of bismuth quadruple therapy often result in poor compliance, which limited the applicability of this recommendation. We previously showed that the efficacy of bismuth-containing quadruple therapy with minocycline and metronidazole was not inferior to classical bismuth quadruple therapy for refractory H. pylori infection, though also accompanied with high occurrence of adverse events.This study aimed to evaluate the efficacy and tolerability of four different regimens with minocycline and metronidazole compared to classical bismuth quadruple therapy for H. pylori rescue treatment in a real-world setting.